| [1] |
Colombo C, Littlewood J. The implementation of standards of care in Europe: state of the art. J Cyst Fibros, 2011, 10 Suppl 2: S7-S15. doi:10.1016/s1569-1993(11)60003-9.
|
| [2] |
囊性纤维化诊断与治疗中国专家共识编写组, 中国罕见病联盟呼吸病学分会, 中国支气管扩张症临床诊治与研究联盟. 囊性纤维化诊断与治疗中国专家共识(2023版). 中华结核和呼吸杂志, 2023, 46(4): 352-372. doi:10.3760/cma.j.cn112147-20221214-00971.
|
| [3] |
Schnitker F, Liu Y, Keitsch S, et al. Reduced Sphingosine in Cystic Fibrosis Increases Susceptibility to Mycobacterium abscessus Infections. Int J Mol Sci, 2023, 24(18):14004. doi:10.3390/ijms241814004.
|
| [4] |
Bryant JM, Brown KP, Burbaud S, et al. Stepwise pathogenic evolution of Mycobacterium abscessus. Science, 2021, 372(6541):eabb8699. doi:10.1126/science.abb8699.
|
| [5] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11): 918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
|
| [6] |
时翠林, 张建平, 唐佩军, 等. 脓肿分枝杆菌肺病治疗研究进展. 中华结核和呼吸杂志, 2021, 44(3): 252-257. doi:10.3760/cma.j.cn112147-20210108-00020.
|
| [7] |
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1):2000535. doi:10.1183/13993003.00535-2020.
|
| [8] |
Guo X, Liu K, Liu Y, et al. Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases. Orphanet J Rare Dis, 2018, 13(1):224. doi:10.1186/s13023-018-0968-2.
pmid: 30558651
|
| [9] |
Shi R, Wang X, Lu X, et al. A systematic review of the clinical and genetic characteristics of Chinese patients with cystic fibrosis. Pediatr Pulmonol, 2020, 55(11): 3005-3011. doi:10.1002/ppul.24980.
|
| [10] |
Recchia D, Stelitano G, Stamilla A, et al. Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options. Int J Mol Sci, 2023, 24(5):4635. doi:10.3390/ijms24054635.
|
| [11] |
Mauch RM, Jensen P, Qvist T, et al. Adaptive Immune Response to Mycobacterium abscessus Complex (MABSC) in Cystic Fibrosis and the Implications of Cross-Reactivity. Front Cell Infect Microbiol, 2022, 12:858398. doi:10.3389/fcimb.2022.858398.
|
| [12] |
沙巍, 梁莉, 蒋瑞华, 等. 含头孢西丁方案治疗高度耐药的快速生长型非结核分枝杆菌肺部感染16例疗效观察. 中华结核和呼吸杂志, 2011, 34(4): 265-268. doi:10.3760/cma.j.issn.1001-0939.2011.04.011.
|
| [13] |
Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J, 2019, 54(1):1801991. doi:10.1183/13993003.01991-2018.
|
| [14] |
Kwon YS, Levin A, Kasperbauer SH, et al. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Respir Med, 2019, 158: 89-91. doi:10.1016/j.rmed.2019.10.006.
|
| [15] |
Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest, 2015, 148(2): 499-506. doi:10.1378/chest.14-2764.
pmid: 25675393
|
| [16] |
Sarathy JP, Ganapathy US, Zimmerman MD, et al. TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother, 2020, 64(4):e02404-19. doi:10.1128/aac.02404-19.
|
| [17] |
Duah M, Beshay M. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series. Int J Infect Dis, 2022, 122: 953-956. doi:10.1016/j.ijid.2022.06.061.
|
| [18] |
Rizzo AR, Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. BMC Infect Dis, 2022, 22(1):874. doi:10.1186/s12879-022-07857-7.
|
| [19] |
Tang YW, Cheng B, Yeoh SF, et al. Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study. Front Microbiol, 2018, 9: 2095. doi:10.3389/fmicb.2018.02095.
|
| [20] |
Dedrick RM, Smith BE, Cristinziano M, et al. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clin Infect Dis, 2023, 76(1): 103-112. doi:10.1093/cid/ciac453.
|
| [21] |
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med, 2019, 25(5): 730-733. doi:10.1038/s41591-019-0437-z.
|
| [22] |
Nick JA, Dedrick RM, Gray AL, et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell, 2022, 185(11): 1860-1874.e12. doi:10.1016/j.cell.2022.04.024.
|
| [23] |
Ong T, Ramsey BW. Cystic Fibrosis: A Review. JAMA, 2023, 329(21): 1859-1871. doi:10.1001/jama.2023.8120.
pmid: 37278811
|
| [24] |
Tiddens HAWM, Chen Y, Andrinopoulou ER, et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respir Med, 2022, 10(7): 669-678. doi:10.1016/S2213-2600(21)00546-4.
|
京公安网备11010202008787号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
